Prasugrel

Type: Product
Name: Prasugrel
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

TRANSLATE-ACS: No MACE Benefit With Prasugrel in ACS

WASHINGTON, DC — A real-world comparison of clopidogrel vs prasugrel (Effient, Lilly/Daiichi-Sankyo) in nearly 12 000 acute coronary syndrome (ACS) patients undergoing PCI revealed no significant differences in the rate of major adverse cardiovascular ... [Published American Journal of Public Health - Sep 18 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same

The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same. ... [Published Free Patents Online - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

TCT.14: Heparin may come back in vogue, but in low doses

WASHINGTON, D.C.—Heparin is making a comeback in a big way, according to one statement made Sept. 14 at the Transcatheter Cardiovascular Therapeutics (TCT) conference. The speaker went on to say that it will become the anticoagulant of choice over bivalirudin ... [Published Cardiovascular Business - Sep 15 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Ticagrelor vs Clopidogrel in Non-ST-Elevation ACS

Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S Windecker ... [Published Theheart.org - Sep 11 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

New NICE guidance published

September 2014 Volume 21, Issue 3 Br J Cardiol 2014;21:98 Authors:BJCardio StaffAtrial fibrillationThe National Institute for Health and Care Excellence (NICE) has said that thousands of people with atrial fibrillation (AF) could be prevented from having ... [Published British Journal of Cardiology - Sep 02 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Diabetes Mellitus and Clopidogrel Response Variability ∗

Platelet P2Y 12 -receptor antagonists reduce major adverse cardiovascular events after percutaneous coronary intervention (PCI) and in acute coronary syndrome (ACS) ( 1 – 4 ). Together with aspirin, they are the cornerstones of adjunctive medical therapy ... [Published Journal of the American College of Cardiology - Sep 01 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction

Effective antiplatelet therapy combining the inhibition of both thromboxane A2–dependent platelet aggregation and P2Y12 receptors is necessary in patients undergoing percutaneous coronary intervention (PCI), particularly those with ST-segment elevation ... [Published DailyMe.Com - Sep 01 2014]
First reported Aug 25 2014 - Updated Aug 26 2014 - 3 reports

NPPA grants price exemption for Torrent Pharma's FDC drug

Torrent Pharma has apparently become the first company to receive price exemption for a new drug from National Pharmaceutical Pricing Authority (NPPA) under the new drug pricing policy, which came into effect last year, according to a Business Standard. ... [Published Business Standard India - Aug 26 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

TEVA PHARMACEUTICAL : Patent Issued for Crystalline Forms of Prasugrel Salts

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Alexandria, Virginia , by NewsRx journalists, a patent by the inventors Tuksar, Mihaela (Cakovec, HR); Biljan, Tomislav (Krizevci, HR); Zegarac, ... [Published 4 Traders - Aug 21 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

EFFIENT (Prasugrel Hydrochloride) Tablet, Film Coated [Eli Lilly And Company ]

First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel

Related Biotechnology, Pharmaceutical and Healthcare NewsRevised guidance from the National Institute for Health and Care Excellence, recommends once-daily, oral antiplatelet prasugrel (Efient®)...Original Article: NEXT ARTICLE More From BioPortfolio ... [Published BioPortfolio - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Daiichi Sankyo and Eli Lilly and Company: Heart patients in England and Wales offered more choice of therapies as NICE extends recommendations for prasugrel

GERRARDS CROSS, England--(BUSINESS WIRE)--Revised guidance from the National Institute for Health and Care Excellence (NICE), recommends once-daily, oral antiplatelet prasugrel (Efient®), in combination with aspirin, as a cost-effective option when compared ... [Published Business Wire Health News - Jul 23 2014]

Quotes

"There has definitely been more uptake of these more potent antiplatelet therapies," added Wang. "In the US, a lot of it is driven by socioeconomic factors"
...a systematic review of the evidence including 100 trials in 93 553 patients with 262 090 patient years in the field of coronary revascularisation. "The key finding was that among patients with stable CAD, coronary artery bypass grafting (CABG) reduces the risk of death, myocardial infarction and repeat revascularisation compared with medical treatment" Professors Kolh and Windecker said
...measured by thermogravimetric analysis--'TGA', or differential scanning calorimetry-- "DSC'), x-ray diffraction pattern, e g., powder x-ray diffraction (PXRD), infrared absorption fingerprint (IR), and solid state NMR spectrum. One or more of these techniques may be used to distinguish different polymorphic forms of a compound."

More Content

All (33) | News (25) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
TRANSLATE-ACS: No MACE Benefit With Prasugrel i... [Published American Journal of Public Health - Sep 18 2014]
Pharmaceutical compositions comprising prasugre... [Published Free Patents Online - Sep 16 2014]
Long-term Dual-Antiplatelet Treatment After DES... [Published General Medicine eJournal - Sep 16 2014]
TCT.14: Heparin may come back in vogue, but in ... [Published Cardiovascular Business - Sep 15 2014]
Ticagrelor vs Clopidogrel in Non-ST-Elevation ACS [Published Theheart.org - Sep 11 2014]
TCT 2014 Late-breaking Trials and First Report ... [Published Diagnostic & Invasive Cardiology - Sep 09 2014]
New NICE guidance published [Published British Journal of Cardiology - Sep 02 2014]
Diabetes Mellitus and Clopidogrel Response Vari... [Published Journal of the American College of Cardiology - Sep 01 2014]
Prehospital Ticagrelor in ST-Segment Elevation ... [Published DailyMe.Com - Sep 01 2014]
Prehospital Ticagrelor in ST-Segment Elevation ... [Published New England Journal of Medicine - Sep 01 2014]
ESC/EACTS revascularization guidelines stress b... [Published EurekAlert! - Aug 30 2014]
NPPA grants price exemption for Torrent Pharma'... [Published Business Standard India - Aug 26 2014]
Torrent Pharma gets price exemption for new FDC... [Published FirstWord Pharma - Aug 25 2014]
Torrent Pharma gets price exemption for new FDC... [Published Business Standard India - Aug 25 2014]
TEVA PHARMACEUTICAL : Patent Issued for Crystal... [Published 4 Traders - Aug 21 2014]
BRISTOL MYERS SQUIBB : Studies from Bristol-Mye... [Published 4 Traders - Aug 20 2014]
TEVA PHARMACEUTICAL : Assigned Patent [Published 4 Traders - Aug 14 2014]
EFFIENT (Prasugrel Hydrochloride) Tablet, Film ... [Published DailyMed Drug Label Updates for the last seven ... - Aug 12 2014]
Heart patients in England and Wales offered mor... [Published BioPortfolio - Jul 24 2014]
NICE recommends drugs for blood clots and const... [Published BioPortfolio - Jul 24 2014]
Daiichi Sankyo and Eli Lilly and Company: Heart... [Published Business Wire Health News - Jul 23 2014]
Industry up in arms against NPPA for bringing 1... [Published PharmaBiz - Jul 15 2014]
Court Report [Published Patent Docs - Jul 07 2014]
Net earnings of 5 leading Japanese pharma compa... [Published PharmaBiz - Jul 04 2014]
Court Report - Part III [Published Patent Docs - Apr 25 2014]
Top medicine articles for April 2014 [Published Clinical Cases and Images: CasesBlog - Apr 17 2014]
Acute coronary syndrome - prasugrel with PCI (r... [Published NICE | National Institute for Health and Clinic ... - Apr 01 2014]
Personalized Medicine Study for Heart Attack Pa... [Published PRWeb - Mar 18 2014]
Snowball Effect: The Incidence of Premature Par... [Published FDA Law Blog - Mar 17 2014]
Spartan Bioscience Announces Collaboration With... [Published PRWeb - Mar 05 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
EFFIENT (Prasugrel Hydrochloride) Tablet, Film ... [Published DailyMed Drug Label Updates for the last seven ... - Aug 12 2014]
Updated Date: Aug 12, 2014 EST ...
Daiichi Sankyo and Eli Lilly and Company: Heart... [Published Business Wire Health News - Jul 23 2014]
GERRARDS CROSS, England--(BUSINESS WIRE)--Revised guidance from the National Institute for Health and Care Excellence (NICE), recommends once-daily, oral antiplatelet prasugrel (Efient®), in combination with aspirin, as a cost-effective option when compared ...
Court Report [Published Patent Docs - Jul 07 2014]
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Eli Lilly and Company et al. v. Panacea Biotec, Ltd. 1:14-cv-01064; filed June 26, 2014 in the Southern District of Indiana•Plaintiffs: ...
Court Report - Part III [Published Patent Docs - Apr 25 2014]
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Eli Lilly and Company et al. v. Apotex Corp. et al. 1:14-cv-00586; filed April 16, 2014 in the Southern District of Indiana•Plaintiffs: ...
Top medicine articles for April 2014 [Published Clinical Cases and Images: CasesBlog - Apr 17 2014]
A collection of some interesting medical articles published recently:Noninfluenza Vaccination Rates Among U.S. Adults Remain Low - only 16% for Tdap in 2012 http://buff.ly/NcduqD Adult Tonsillectomy Shown to Be Safe: 30-day mortality rate was low, ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.